We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current AKRO market cap is 3.53B. The company's latest EPS is USD -2.1742 and P/E is -23.23.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -46.62M | -61.87M | -59.95M | -65.74M | -81.7M |
| Net Income | -39.66M | -55.19M | -53.34M | -55.99M | -72.71M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -45.65M | -80.15M | -100.89M | -115.16M | -172.87M |
| Net Income | -43.76M | -79.21M | -100.78M | -112.03M | -151.76M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 635.33M | 580.27M | 912.24M | 865.04M | 817.55M |
| Total Liabilities | 52.2M | 44.97M | 65.99M | 66.98M | 79.22M |
| Total Equity | 583.14M | 535.31M | 846.25M | 798.07M | 738.33M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 138.12M | 273.34M | 195.55M | 356.57M | 580.27M |
| Total Liabilities | 9.39M | 14.63M | 26.44M | 30.01M | 44.97M |
| Total Equity | 128.73M | 258.71M | 169.11M | 326.56M | 535.31M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -96.74M | -145.37M | -35.14M | -92.59M | -163.02M |
| Investing | -236.41M | -223.62M | 57.85M | -198.05M | -124.98M |
| Financing | 352.81M | 353.32M | 366.94M | 366.79M | 369.86M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -35.63M | -70.8M | -79.68M | -92.52M | -145.37M |
| Investing | -71.51M | -9.76M | 42.28M | -63.83M | -223.62M |
| Financing | 95.99M | 203.11M | 602k | 255.63M | 353.32M |
| Market Cap | 3.53B |
| Price to Earnings Ratio | -23.23 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 15.05 |
| Price to Book Ratio | 6.58 |
| Dividend Yield | - |
| Shares Outstanding | 69.8M |
| Average Volume (1 week) | 1.21M |
| Average Volume (1 Month) | 2.34M |
| 52 Week Change | 145.36% |
| 52 Week High | 58.40 |
| 52 Week Low | 17.86 |
| Spread (Intraday) | 5.12 (9.85%) |
| Company Name | Akero Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.akerotx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
